Skip to main
NVAX
NVAX logo

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 31%
Buy 19%
Hold 31%
Sell 6%
Strong Sell 13%

Bulls say

Novavax Inc. is experiencing growth potential in the post-COVID-19 vaccine market, evidenced by a lucrative licensing deal with Sanofi that could generate up to $1.2 billion and the company capturing 3% market share this season, despite aiming for 5%. The announcement of their 3Q24 financial results indicates effective cost management and a refinement in R&D strategy, positioning the firm to extend its offerings beyond COVID-19 vaccines. Furthermore, Novavax is implementing additional cost reduction measures aimed at lowering operating expenses to below $500 million by 2025, enhancing its long-term operational viability.

Bears say

Novavax Inc reported a significant net loss of $121.3 million for the third quarter of 2024, equating to a loss of $0.76 per share, which was below market expectations. Additionally, the company's revenue forecast for the fourth quarter of 2024 has been notably revised downward from $152.5 million to $88.8 million, reflecting growing uncertainties in product sales. Various risks, including potential failures in clinical trials, regulatory hurdles, and challenges in commercialization and intellectual property, contribute to an overall negative outlook for the company's financial performance.

Novavax (NVAX) has been analyzed by 16 analysts, with a consensus rating of Hold. 31% of analysts recommend a Strong Buy, 19% recommend Buy, 31% suggest Holding, 6% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 16 analysts, Novavax (NVAX) has a Hold consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.